tspan33 Antibody

What is TSPAN33 and what is its significance in human immune function?

TSPAN33 (Tetraspanin 33) is a transmembrane protein belonging to the tetraspanin superfamily, characterized by four conserved transmembrane regions. It functions primarily as a B cell activation marker with restricted expression patterns. Unlike other B cell antigens such as CD20 and CD19 that are expressed in both resting and activated B cells, TSPAN33 is specifically expressed in activated B cells, making it a valuable marker for B cell activation status . TSPAN33 plays important roles in:

• B cell activation processes following stimulation with anti-CD40 and IL-4

• Regulation of B-lymphocyte cytoskeleton and plasma membrane phenomena

• Modulation of cell adhesion, protrusion formation, and migration behaviors

• Control of mechanical properties of the plasma membrane

TSPAN33 belongs to the TSPANC8 subfamily, which includes TSPAN5, TSPAN10, TSPAN14, TSPAN15, and TSPAN17, and has been implicated in interactions with ADAM10 .

How is TSPAN33 expression regulated in normal B cells versus malignant B cells?

In normal B cell biology, TSPAN33 expression is tightly regulated:

• Resting B cells show minimal to undetectable TSPAN33 expression

• Upon activation (e.g., with anti-CD40 + IL-4), B cells significantly upregulate TSPAN33 expression, with over 40-fold higher mRNA levels compared to resting B cells

• Protein expression increases approximately 5-fold following activation

• The upregulation is sustained for extended periods (up to 120 hours) following stimulation in cell models

In malignant contexts, TSPAN33 shows distinctive expression patterns:

• Highly expressed in several B cell lymphomas, including Hodgkin's Lymphoma (HL) and Diffuse Large B Cell Lymphoma (DLBCL)

• In Hodgkin's Lymphoma, TSPAN33 is localized to Reed-Sternberg cells

• DLBCL shows uniform TSPAN33 expression

• Mantle cell lymphoma is typically negative for TSPAN33 expression

This differential expression pattern makes TSPAN33 a potential diagnostic biomarker for specific lymphoma subtypes.

What methods are effective for detecting TSPAN33 in different sample types?

Several methodological approaches have been validated for TSPAN33 detection:

For optimal results, researchers should note that some early polyclonal antibodies worked well for Western blot and IHC but not for FACS analysis. Modern monoclonal antibodies (e.g., clone 545422) have overcome these limitations .

What are the optimal conditions for inducing TSPAN33 expression in B cell models?

Based on published research, the following stimulation conditions effectively induce TSPAN33 expression:

Human B cells:

• Anti-CD40 antibody + IL-4 (overnight or 12+ hours): induces significant upregulation in primary human B cells and 2E2 cell line

• Sustained elevation observed for up to 120 hours post-stimulation

Mouse B cells:

• LPS + IL-4: Shows dose-dependent increase in expression

  • 0.1 ng/mL: ~50-fold increase

  • 1-10 ng/mL: >100-fold increase

• CD40L + IL-4: Effective for stimulating TSPAN33 expression in splenocytes

• Anti-IgD + IL-4: Also induces significant upregulation

For experimental controls, researchers should note that T cell stimulation (anti-CD3 + anti-CD28 or PMA + ionomycin) does not induce TSPAN33 expression, confirming its B cell-specific nature .

How should researchers optimize antibody detection protocols for TSPAN33?

When working with TSPAN33 antibodies, researchers should consider the following methodological optimizations:

For Flow Cytometry:

• Use specialized PE-conjugated antibodies (e.g., clone 545422)

• Co-stain with B cell markers (e.g., CD19) to identify B cell populations

• Include proper isotype controls (e.g., Mouse IgG2B PE isotype)

• For stimulation experiments, include both unstimulated and stimulated conditions to observe the differential expression

For IHC Applications:

• Perform antigen retrieval using either:

  • TE buffer pH 9.0 (preferred) or

  • Citrate buffer pH 6.0 (alternative)

• Titrate antibody dilutions between 1:20-1:200 for optimal signal-to-noise ratio

• Include positive controls (e.g., Hodgkin's lymphoma tissue) and negative controls (e.g., mantle cell lymphoma)

For Western Blot:

• Be aware that TSPAN33 often appears at 64-72 kDa (higher than the calculated 32 kDa), likely due to dimerization or post-translational modifications

• Use 1:200-1:1000 antibody dilution range

• Include positive controls such as activated B cell lysates

What are the key considerations when using TSPAN33 antibodies for distinguishing B cell activation states?

When using TSPAN33 antibodies to evaluate B cell activation:

• Temporal aspects: Consider the kinetics of TSPAN33 expression

  • Expression begins within hours of activation

  • Peaks and remains elevated for extended periods (up to 120 hours)

  • Time points should be selected based on the specific research question

• Co-expression analysis:

  • Combine TSPAN33 staining with other activation markers for comprehensive profiling

  • Consider dual staining with CD19 to confirm B cell identity

  • Include additional markers like CD40, CD80/86, or HLA-DR for activation status

• Sample selection considerations:

  • Fresh samples are preferable for flow cytometry applications

  • For archived samples, consider the stability of TSPAN33 epitopes

  • Fixed samples may require specialized epitope retrieval techniques

• Quantitative analysis:

  • Use appropriate controls to establish gating strategies for flow cytometry

  • Consider relative expression levels rather than simple positive/negative designation

  • Correlate TSPAN33 expression with functional readouts when possible

How does TSPAN33 expression correlate with B cell functional properties?

Recent research has revealed multiple functional implications of TSPAN33 expression in B cells:

Membrane and cytoskeletal dynamics:

• TSPAN33 regulates B cell membrane properties, including tension and roughness

• During fibronectin-induced spreading, TSPAN33 expression inhibits changes in membrane characteristics

• The protein localizes to specific cellular compartments, including membrane microvilli, Golgi apparatus, and extracellular vesicles

Cellular migration and adhesion:

• TSPAN33 overexpression enhances migratory capacity, as demonstrated by increased chemotaxis and invasion rates

• This occurs through altered cell adhesion properties resulting from aberrant integrin expression

• TSPAN33 knockdown produces opposite phenotypes, confirming its regulatory role

Endocytic processes:

• TSPAN33 expression affects phagocytic ability of B cells

• Overexpression leads to diminished phagocytosis

• This suggests TSPAN33 may regulate antigen capture and processing functions

These functional correlations suggest TSPAN33 acts as a master regulator of B cell mechanical properties and behavior, with implications for both normal immune function and pathological conditions.

How can researchers distinguish between TSPAN33 expression patterns in different B cell malignancies?

TSPAN33 demonstrates distinct expression patterns across B cell malignancies that can be leveraged for differential diagnosis:

When designing experiments to differentiate between lymphoma types:

• Multi-marker panels: Combine TSPAN33 with established lymphoma markers

  • For HL: CD30, CD15, PAX5

  • For DLBCL: CD20, CD79a, BCL6

  • For mantle cell lymphoma: CD5, cyclin D1

• Spatial distribution analysis:

  • Pay particular attention to the localization pattern, especially the distinctive Reed-Sternberg cell localization in HL

  • Uniform versus heterogeneous staining can provide diagnostic clues

• Quantitative assessment:

  • Consider both the percentage of positive cells and staining intensity

  • Digital pathology tools can provide more objective quantification

What are the methodological challenges in studying TSPAN33's role in membrane mechanics and how can they be addressed?

Investigating TSPAN33's influence on membrane mechanics presents several technical challenges:

Challenge 1: Visualizing membrane-cytoskeleton interactions

• Solution: Employ super-resolution microscopy techniques (STORM, PALM, SIM) to visualize tetraspanin-enriched microdomains at nanoscale resolution

• Approach: Combine TSPAN33 labeling with cytoskeletal markers (actin, spectrin) and membrane tension probes

Challenge 2: Measuring membrane mechanical properties

• Solution: Implement biophysical techniques including:

  • Atomic force microscopy to quantify membrane stiffness

  • Optical tweezers to measure membrane tension

  • Tether pulling assays to determine membrane-cytoskeleton adhesion strength

• Approach: Compare these properties between TSPAN33-overexpressing, knockdown, and control cells

Challenge 3: Determining functional relationships rather than correlations

• Solution: Develop conditional and inducible expression systems

  • Use Tet-ON/OFF systems for temporal control of TSPAN33 expression

  • Employ domain-specific mutations to identify critical regions for membrane mechanics

• Approach: Monitor real-time changes in cell behavior upon modulation of TSPAN33 expression

Challenge 4: Translating in vitro findings to physiological contexts

• Solution: Develop advanced 3D culture systems and in vivo models

  • 3D matrices of varying stiffness to mimic different tissue environments

  • Intravital imaging of TSPAN33-expressing cells in animal models

• Approach: Correlate membrane properties with migration behavior in complex environments

How does TSPAN33 expression in autoimmune conditions differ from expression in B cell malignancies?

TSPAN33 displays distinctive patterns in autoimmune conditions compared to malignancies:

Autoimmune Conditions:

• Expressed in B cells from rheumatoid arthritis patients

• Detectable in B cells from systemic lupus erythematosus (SLE) patients

• Upregulated in spleen B cells from MRL/Fas lpr/lpr mice (a mouse model of SLE)

• Expression likely reflects the activated state of autoreactive B cells

B Cell Malignancies:

• In lymphomas, expression reflects the activation state of the malignant cell of origin

• HL shows localized expression in Reed-Sternberg cells

• DLBCL shows uniform expression patterns

• Mantle cell lymphoma is typically negative

The key difference appears to be the expression pattern and context:

• In autoimmune conditions, TSPAN33 is linked to pathological B cell activation

• In malignancies, expression reflects the developmental origin and activation state of the transformed cell

This differential expression suggests TSPAN33 may serve as a biomarker for distinguishing between activated B cells in autoimmune diseases versus malignant B cells in lymphomas.

What experimental models are most suitable for studying TSPAN33's role in lymphomagenesis?

Researchers investigating TSPAN33's potential contributions to lymphoma development should consider the following experimental models:

In vitro cellular models:

• 2E2 B cell line: Human Burkitt's lymphoma-derived model that upregulates TSPAN33 upon activation with anti-CD40 + IL-4

• DLBCL cell lines: Express high levels of TSPAN33 and can be used for functional studies

• HL cell lines (L428, KM-H2): Contain Reed-Sternberg cells that express TSPAN33

Genetic modification approaches:

• CRISPR/Cas9-mediated knockout or knockin of TSPAN33 in lymphoma cell lines

• Inducible expression systems to study dose-dependent effects

• Domain-specific mutations to identify critical regions for lymphoma-promoting activities

Animal models:

• Transgenic mice with B cell-specific TSPAN33 overexpression

• Xenograft models using modified lymphoma cell lines with altered TSPAN33 expression

• Patient-derived xenografts from lymphoma subtypes with different TSPAN33 expression patterns

Ex vivo patient samples:

• Primary lymphoma samples from different subtypes

• Sequential samples to track TSPAN33 expression during disease progression

• Paired samples of diagnostic and relapsed disease to assess changes in expression

The choice of model should be guided by the specific research question, with consideration of the lymphoma subtype of interest and the particular aspect of TSPAN33 biology being investigated.

How can researchers integrate TSPAN33 analysis with other biomarkers for comprehensive B cell lymphoma classification?

For comprehensive lymphoma classification incorporating TSPAN33:

Multiparameter analysis approaches:

• Multiplex immunohistochemistry panels:

  • Combine TSPAN33 with established lymphoma markers (CD20, CD30, BCL6, etc.)

  • Include markers for cell of origin classification (e.g., GCB vs. ABC markers for DLBCL)

  • Implement digital pathology tools for objective quantification

• Flow cytometry panels:

  • Design panels that include TSPAN33 alongside standard B cell markers

  • Include markers of B cell activation state and differentiation

  • Consider intracellular signaling markers to correlate with TSPAN33 expression

• Multi-omics integration:

Through these integrated approaches, TSPAN33 analysis can enhance the precision of lymphoma classification beyond traditional histopathological assessment, potentially revealing distinct molecular subtypes with clinical relevance.

What are the common technical challenges when working with TSPAN33 antibodies and how can they be resolved?

Researchers may encounter several technical issues when working with TSPAN33 antibodies:

For optimal results when evaluating B cell activation via TSPAN33:

• Include suitable positive controls (e.g., B cells stimulated with anti-CD40+IL-4)

• Use paired unstimulated samples as negative controls

• Consider time-course experiments to capture the kinetics of TSPAN33 upregulation

How should researchers interpret contradictory TSPAN33 expression data between different detection methods?

When faced with discrepancies in TSPAN33 detection across different methods:

Methodological considerations:

• Transcriptional vs. Protein Expression:

  • qRT-PCR measures mRNA which may not directly correlate with protein levels

  • Post-transcriptional regulation may cause discrepancies between mRNA and protein

  • Solution: Perform both analyses on the same samples to establish correlation patterns

• Antibody Epitope Accessibility:

  • Different antibody clones recognize distinct epitopes that may be differentially accessible

  • Fixation and preparation methods affect epitope availability

  • Solution: Compare multiple antibody clones targeting different regions of TSPAN33

• Detection Sensitivity Thresholds:

  • Flow cytometry, Western blot, and IHC have different detection thresholds

  • Low expression may be detectable by qRT-PCR but below threshold for protein methods

  • Solution: Use the most sensitive method appropriate for your research question

Analytical approach to resolving contradictions:

• Verify technical variables (antibody lot, protocol differences, sample preparation)

• Perform titration experiments to determine optimal antibody concentration for each method

• Consider biological variables (activation state, sample timing, cell heterogeneity)

• Use orthogonal approaches (e.g., fluorescent protein tagging) to validate expression patterns

• When reporting contradictory results, clearly describe methodological differences that may account for discrepancies

What are the critical parameters for successfully detecting TSPAN33 in extracellular vesicles and membrane microdomains?

Detecting TSPAN33 in specialized membrane compartments requires specific methodological considerations:

For extracellular vesicle (EV) detection:

• Isolation techniques:

  • Differential ultracentrifugation remains the gold standard

  • Consider size exclusion chromatography for higher purity

  • Commercial precipitation kits may be used but validate with multiple markers

• Verification methods:

  • Confirm EV identity using markers (CD63, CD81, TSG101)

  • Characterize size distribution using nanoparticle tracking analysis

  • Verify morphology by transmission electron microscopy

• TSPAN33 detection in EVs:

  • Western blot may require concentration of multiple EV fractions

  • Consider highly sensitive techniques like ExoScreen or ExoView

  • Flow cytometry requires EV capture on beads or specialized cytometers

For membrane microdomain analysis:

• Isolation approaches:

  • Detergent-resistant membrane fractions via sucrose gradient ultracentrifugation

  • Non-detergent methods using pH modification or mechanical disruption

  • Immunoprecipitation of tetraspanin-enriched microdomains

• Visualization techniques:

  • Super-resolution microscopy to overcome diffraction limits

  • Proximity ligation assays to detect protein-protein interactions in situ

  • Fluorescence recovery after photobleaching (FRAP) to assess membrane dynamics

• Critical controls:

  • Include known tetraspanin partners (CD81, CD82) as positive controls

  • Use cholesterol depletion to disrupt microdomains as negative control

  • Employ multiple detergent conditions to validate microdomain associations

These specialized approaches enable researchers to characterize TSPAN33's distribution and function in membrane subdomains that are critical to its biological activity in B cells.